



These additions and changes are effective 10/11/24

Pharmacy Benefit Additions (these apply to Exchange only):

Filsuvez (birch triterpenes) – Pharmacy benefit, Non-Preferred brand, PA

Liraglutide generic – Pharmacy benefit, Non-Formulary

Myhibbin (mycophenolate mofetil) – Pharmacy benefit, Non-Formulary

Ojemda (tovorafenib) (tablet and suspension) – Pharmacy benefit, Non-Preferred brand, PA

Opsynvi (macitentan/tadalafil) – Pharmacy benefit, Non-Formulary

Retevmo (selpercatinib) (tablet) – Pharmacy benefit, Non-Preferred brand, PA

Rezdiffra (resmetirom) – Pharmacy benefit, Non-Preferred brand, PA

Simlandi (adalimumab-ryvk) – Pharmacy benefit, Non-Formulary

Voydeya (danicopan) – Pharmacy benefit, Non-Preferred brand, PA

Winrevair (sotatercept) – Pharmacy benefit, Non-Preferred brand, PA

Pharmacy Benefit Changes (these apply to Exchange only):

Entyvio – Pharmacy benefit, New indication, Crohn's disease

Fasenra (benrakuzumab) – Pharmacy benefit, Criteria updates, Age update

Livmarli (maralixibat) – Pharmacy benefit, New indication, progressive familial intrahepatic cholestasis (PFIC)

Nexletol (bempedoic acid) – Pharmacy benefit, New indication, Established CVD or high risk for a CVD event

Nexlizet (bempedoic acid and ezetimibe) – Pharmacy benefit, New indication, Established CVD or high risk for a CVD event

Praluent (alirocumab) – Pharmacy benefit, Criteria update, remove specialist requirement

Repatha (evolocumab) – Pharmacy benefit, Criteria update, remove specialist requirement

Xolair (omalizumab) – Pharmacy benefit, New indication, IgE-mediated food allergy

Medical Benefit Additions/Changes (these apply to Medicare and Exchange):

Eribulin – Medical benefit, PA

Imdelltra (tarlatamab-dlle) – Medical benefit, PA

Rytelo (imetelstat) – Medical benefit, PA

Xolair (omalizumab) – Medical benefit, New indication, IgE-mediated food allergy